$553 Million is the total value of Essex Woodlands Management, Inc.'s 9 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RVNC | Sell | REVANCE THERAPEUTICS INC | $137,353,000 | +8.6% | 3,842,047 | -16.3% | 24.83% | +10.6% |
| ABMD | Sell | ABIOMED INC | $121,220,000 | -24.1% | 646,818 | -31.7% | 21.91% | -22.6% |
| AXGN | Sell | AXOGEN INC | $105,024,000 | +11.7% | 3,711,111 | -23.7% | 18.98% | +13.8% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDICINOVA INC | 42 | Q3 2023 | 6.5% |
| REVANCE THERAPEUTICS INC | 39 | Q3 2023 | 44.6% |
| AXOGEN INC | 26 | Q4 2021 | 43.3% |
| ENDOLOGIX INC | 24 | Q1 2019 | 22.5% |
| ABIOMED INC | 20 | Q1 2018 | 52.1% |
| CORIUM INTL INC | 20 | Q1 2019 | 23.5% |
| TELA BIO, INC. | 16 | Q3 2023 | 31.5% |
| VENUS CONCEPT, INC. | 16 | Q3 2023 | 21.3% |
| ACURA PHARMACEUTICALS INC | 15 | Q1 2019 | 1.4% |
| CATALYST BIOSCIENCES INC | 15 | Q1 2019 | 1.0% |
View Essex Woodlands Management, Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Essex Woodlands Management, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.